Streetbeat News

Products Services

KIND

Nextdoor Holdings, Inc. has appointed Georg Petschnigg as Chief Design Officer to lead its design strategy and execution. This move is part of a broader transformation initiative called NEXT.

Portfolio Pulse from

November 06, 2024 | 9:30 pm

KD

Kyndryl exceeded second-quarter revenue estimates due to strong demand for its consulting services, particularly from businesses adopting generative AI technology.

Portfolio Pulse from

November 06, 2024 | 9:30 pm

TRVI

Trevi Therapeutics has completed enrollment for its Phase 2a RIVER trial in refractory chronic cough and is halfway through enrollment for its Phase 2b CORAL trial in chronic cough related to idiopathic pulmonary fibrosis. The company ended Q3 2024 with $65.5 million in cash, providing a cash runway into the second half of 2026.

Portfolio Pulse from

November 06, 2024 | 9:30 pm

HOVR

Horizon Aircraft, a developer of hybrid electric eVTOL aircraft, will participate in the 13th Annual Roth Technology Conference in New York City. The company's CEO and COO will conduct meetings on November 20, 2024.

Portfolio Pulse from

November 06, 2024 | 9:30 pm

TNYA

Tenaya Therapeutics released its Q3 2024 financial results and provided a business update. The Data Safety and Monitoring Board has endorsed dose escalation and broadening of inclusion criteria in the MyPEAK TM -1 Phase 1b/2 trial of TN-201 gene therapy.

Portfolio Pulse from

November 06, 2024 | 9:30 pm

LYFT

Lyft reported strong Q3 2024 financial results and raised its full-year outlook, highlighting innovations and partnerships as key drivers of success.

Portfolio Pulse from

November 06, 2024 | 9:30 pm

FTEK

Fuel Tech, Inc. (NASDAQ: FTEK) has been awarded air pollution control orders worth $2.0 million from customers in the US, Europe, and Southeast Asia.

Portfolio Pulse from

November 06, 2024 | 9:30 pm

ALGS

Aligos Therapeutics, a clinical stage biopharmaceutical company, reported its business progress and financial results for Q3 2024, focusing on therapies for liver and viral diseases.

Portfolio Pulse from

November 06, 2024 | 9:30 pm

RGNX

REGENXBIO reported its Q3 2024 financial results and provided updates on its clinical trials. Key developments include the advancement of RGX-202 for Duchenne Muscular Dystrophy, the initiation of a BLA submission for RGX-121, and positive Phase II data for ABBV-RGX-314. An end-of-Phase II meeting for ABBV-RGX-314 in diabetic retinopathy is accelerated to Q4 2024.

Portfolio Pulse from

November 06, 2024 | 9:30 pm

FRSH

Freshworks Inc. (NASDAQ: FRSH) announced its financial results for the third quarter of 2024, highlighting its performance as a provider of AI service software.

Portfolio Pulse from

November 06, 2024 | 9:30 pm